Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $820.00 Price Target at Truist Financial

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price increased by Truist Financial from $798.00 to $820.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Other research analysts also recently issued reports about the stock. Cantor Fitzgerald increased their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 20th. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. Scotiabank upped their target price on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research report on Monday, November 24th. Finally, Citigroup raised their price target on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $791.05.

Regeneron Pharmaceuticals Stock Down 1.4%

Shares of NASDAQ REGN opened at $801.01 on Thursday. The business has a 50-day moving average of $735.23 and a two-hundred day moving average of $626.08. The company has a market capitalization of $84.19 billion, a price-to-earnings ratio of 19.18, a price-to-earnings-growth ratio of 2.42 and a beta of 0.39. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $816.99. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter last year, the company earned $12.46 EPS. On average, analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 46.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 8,431 shares of company stock valued at $5,733,521. 7.02% of the stock is owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in REGN. State Street Corp increased its stake in Regeneron Pharmaceuticals by 0.9% in the second quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock valued at $2,536,801,000 after purchasing an additional 42,343 shares during the last quarter. Dodge & Cox grew its holdings in Regeneron Pharmaceuticals by 18.9% in the 3rd quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after buying an additional 724,562 shares during the period. Franklin Resources Inc. increased its stake in shares of Regeneron Pharmaceuticals by 6.0% during the 3rd quarter. Franklin Resources Inc. now owns 2,453,143 shares of the biopharmaceutical company’s stock valued at $1,379,329,000 after acquiring an additional 139,647 shares during the last quarter. Capital World Investors increased its position in Regeneron Pharmaceuticals by 1.6% during the third quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock worth $1,123,609,000 after purchasing an additional 32,348 shares during the last quarter. Finally, Loomis Sayles & Co. L P raised its position in shares of Regeneron Pharmaceuticals by 18.6% in the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock worth $1,019,062,000 after buying an additional 305,089 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America upgraded REGN from Underperform to Buy and lifted its price target to $860, citing improving fundamentals and 2026 catalysts, a clear bullish catalyst for the stock. Regeneron Pharmaceuticals upgraded by Bank of America
• Positive Sentiment: Truist raised its price target to $820 and reiterated a Buy, adding incremental upside and supporting analyst-driven demand. Truist raises price target
• Positive Sentiment: Aggregated analyst coverage is shifting more positive (multiple upgrade pieces and a roundup of 21 analyst views), which can drive buy-side interest and shorten-term momentum. 21 analysts assess Regeneron
• Neutral Sentiment: Unusual options activity has been reported, indicating increased speculative positioning and hedging that can amplify intraday moves but is ambiguous for longer-term direction. Unusual options activity
• Neutral Sentiment: Coverage pieces note falling short interest and renewed bullish cases; lower short interest reduces short-squeeze potential but supports steadier upside if fundamentals hold. Analyst upgrades and short-interest drop
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at ~$800 on Jan. 7, which can be viewed by some investors as a signal to take profits. Director share sale disclosed

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.